DOTARIZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H34N2O2
Molecular Weight	442.5925
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3)CC4(OCCO4)C5=CC=CC=C5

InChI

InChIKey=LRMJAFKKJLRDLE-UHFFFAOYSA-N

InChI=1S/C29H34N2O2/c1-4-11-25(12-5-1)28(26-13-6-2-7-14-26)31-21-19-30(20-22-31)18-10-17-29(32-23-24-33-29)27-15-8-3-9-16-27/h1-9,11-16,28H,10,17-24H2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11164387 | https://www.ncbi.nlm.nih.gov/pubmed/9286620 | Jensen, T.S. (1996) Abstracts, page 501, retrieved from: https://books.google.ru/books?id=8qlpAAAAMAAJ | https://www.ncbi.nlm.nih.gov/pubmed/7623521

Dotarizine was developed as antimigraineur. Dotarizine inhibited the 5-HT2A response in a concentration-dependent manner. The mechanism of blockade by dotarizine of cerebral vessels contractility has three components: (i) presynaptic inhibition of noradrenaline release; (ii) blockade of postsynaptic vascular 5-HT receptors; (iii) blockade of Ca(2+)entry into the vascular smooth muscle cell cytosol. The compound does not affect the vascular receptors for noradrenaline, angiotensin II or prostaglandin F(2alpha). Dotarizine had a pronounced protective effect against electric seizures.

Approval Year

PubMed

Title	Date	PubMed
Ba(2+)-induced chromaffin cell death: cytoprotection by Ca(2+) channel antagonists.	2000 Aug 18	10940353
Pain and psychiatry: a critical analysis and pharmacological review.	2006 Nov 6	17087832

Sample Use Guides

In Vivo Use Guide

Repeated doses of 50 and 10 mg/kg

Route of Administration: Oral

Name

Type

Language

DOTARIZINE

Official Name

English

dotarizine [INN]

Common Name

English

DOTARIZINE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333